38336-06-0

Basic information

• Product Name: Benzenemethanamine, N-[2-(phenylmethoxy)ethyl]-
• CAS NO: 38336-06-0
• Molecular Formula: C16H19NO
• Molecular Weight: 241.333
• Mol File: 38336-06-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzenemethanamine, N-[2-(phenylmethoxy)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, N-[2-(phenylmethoxy)ethyl]-(38336-06-0)
• EPA Substance Registry System: Benzenemethanamine, N-[2-(phenylmethoxy)ethyl]-(38336-06-0)

Safety Data

• Hazardous Substances Data: 38336-06-0(Hazardous Substances Data)

Upstream product

• 105939-43-3 C₁₆H₁₇NO 
• 100-52-7 benzaldehyde 
• 38336-04-8 O-benzylethanolamine 
• 101-06-4 N,N-dibenzyl-2-aminoethanol 
• 60656-87-3 benzyloxyacetoaldehyde 
• 100-46-9 benzylamine 
• 91988-73-7 N,N-dibenzyl-2-(benzyloxy)-1-ethanamine 
• 100-39-0 benzyl bromide 
• 141-43-5 ethanolamine 
• 100-44-7 benzyl chloride 
• 104-63-2 N-Benzylethanolamine 

Downstream Products

• 101709-81-3 N-[2-(Phenylmethoxy)ethyl]-N-(phenylmethyl)glycine, hydrobromide 
• 1221179-25-4 (R)-2-(N-benzyl-N-(2-(benzyloxy)ethyl)amino)-1-(3-nitrophenyl)ethan-1-ol 
• 1221179-26-5 (R)-N-benzyl-N-(2-(benzyloxy)ethyl)-2-(3-nitrophenyl)-2-((triethylsilyl)oxy)ethan-1-amine 
• 104-63-2 N-Benzylethanolamine 
• 883973-50-0 2-[3-benzyl-3-(2-benzyloxy-ethyl)-ureido]-N-methoxy-N-methyl-3-phenyl-propionamide 
• 883973-39-5 (S)-2-[3-Benzyl-3-(2-benzyloxy-ethyl)-ureido]-3-phenyl-propionic acid 
• 883973-95-3 (S)-2-[3-Benzyl-3-(2-benzyloxy-ethyl)-ureido]-3-phenyl-propionic acid methyl ester 
• 38336-04-8 O-benzylethanolamine 

Relevant articles and documents

Chemoselective deprotection of teriary benzylamines and reduction of carbon-carbon double bonds in the presence of benzyl and benzyloxymethyl ethers

Catalytic transfer hydrogenation using 10% Pd-C in the presence of 1,4-cyclohexadiene as the hydrogen donor selectively debenzylates amines and reduces carbon-carbon double bonds while leaving benzyl and benzyloxymethyl ethers intact. (C) 2000 Elsevier Sc

INDAZOLE ANALOGUE

[Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.

INDAZOLE COMPOUNDS

Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.